RT Journal Article
T1 Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
A1 Powles, Thomas
A1 Kockx, Mark
A1 Rodriguez-Vida, Alejo
A1 Duran, Ignacio
A1 Crabb, Simon J
A1 Van Der Heijden, Michiel S
A1 Szabados, Bernadett
A1 Pous, Albert Font
A1 Gravis, Gwenaelle
A1 Herranz, Urbano Anido
A1 Protheroe, Andrew
A1 Ravaud, Alain
A1 Maillet, Denis
A1 Mendez, Maria Jose
A1 Suarez, Cristina
A1 Linch, Mark
A1 Prendergast, Aaron
A1 van Dam, Pieter-Jan
A1 Stanoeva, Diana
A1 Daelemans, Sofie
A1 Mariathasan, Sanjeev
A1 Tea, Joy S
A1 Mousa, Kelly
A1 Banchereau, Romain
A1 Castellano, Daniel
AB An amendment to this paper has been published and can be accessed via a link at the top of the paper.
YR 2020
FD 2020
LK https://hdl.handle.net/10668/25386
UL https://hdl.handle.net/10668/25386
LA en
DS RISalud
RD Apr 6, 2025